Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAM BMT in Children With Non-Malignant Disorders
NCT03128996Phase 2Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Mar 2017
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of hydroxyurea, alemtuzumab, fludarabine, thiotepa, melphalan in sickle cell disease (SCD), bone marrow failure syndrome (BMFS), metabolic disorder, immunological diseases (IMD), hemoglobinopathy, sponsored by Washington University School of Medicine. Started Mar 2017; status: recruiting.
02
Drugs
hydroxyureaalemtuzumabfludarabinethiotepamelphalan
03
Conditions
sickle cell disease (SCD)bone marrow failure syndrome (BMFS)metabolic disorderimmunological diseases (IMD)hemoglobinopathy
Beyond the preview
Go deeper on NCT03128996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03128996.